Fate Therapeutics (FATE) Common Equity (2012 - 2026)

Fate Therapeutics has reported Common Equity for 15 years, with the latest figure at $179.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 37.69% year-over-year to $179.7 million; the trailing twelve-month figure through Mar 2026 stood at $179.7 million (down 37.69% YoY), and the FY2025 full-year result was $207.2 million, down 35.0% from the prior year.
• Common Equity for Q1 2026 stood at $179.7 million, down from $207.2 million in the prior quarter.
• The five-year high for Common Equity was $633.4 million in Q1 2022, with the low at $179.7 million in Q1 2026.
• Historically, Common Equity has averaged $386.9 million across 5 years, with a median of $397.0 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity fell 9.31% — and 2026, when it plunged 37.69%.
• Fate Therapeutics' Common Equity stood at $483.9 million in 2022, then decreased by 23.87% to $368.4 million in 2023, then slipped by 13.49% to $318.7 million in 2024, then sank by 35.0% to $207.2 million in 2025, then fell by 13.26% to $179.7 million in 2026.
• The last three Common Equity figures came in at $179.7 million (Q1 2026), $207.2 million (Q4 2025), and $234.1 million (Q3 2025), per Business Quant data.